Bristol Myers Squibb (CELG-RI) Gains from Investment Securities (2019 - 2025)

Bristol Myers Squibb (CELG-RI) has reported Gains from Investment Securities for 5 consecutive years, with $15.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Gains from Investment Securities changed N/A year-over-year to $15.0 million; the TTM figure through Jun 2026 stood at $351.0 million (up 4.46% YoY), while the FY2025 annual figure was $351.0 million, changed N/A from the prior year.
• Gains from Investment Securities fell to $15.0 million in Q4 2025 per CELG-RI's latest filing, from $336.0 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $336.0 million in Q2 2025 and bottomed at -$510.0 million in Q1 2021.
• Historically, Gains from Investment Securities has averaged -$33.3 million across 3 years, with a median of -$4.5 million in 2022.
• Annual changes were most pronounced in 2021 — Gains from Investment Securities sank 191.73% — and 2022, when it surged 100.2%.
• Bristol Myers Squibb's Gains from Investment Securities stood at -$32.0 million in 2021, then jumped by 68.75% to -$10.0 million in 2022, then jumped by 250.0% to $15.0 million in 2025.
• Business Quant data shows CELG-RI's Gains from Investment Securities at $15.0 million in Q4 2025, $336.0 million in Q2 2025, and -$10.0 million in Q4 2022.